Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. - Wikidata - wikimedia - TriplyDB

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.

http://www.wikidata.org/entity/Q36614881

about

Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Novel immunotherapeutic strategies of gastric cancer treatment The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma-a review.Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer.Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.Gastric cancer and the epoch of immunotherapy approaches A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma.Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy.High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.Predictive and prognostic molecular markers in outcome of esophageal cancer.Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.Small molecule signal transduction inhibitors for the treatment of solid tumors.New and emerging combination therapies for esophageal cancer.Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.ErbB receptors in the biology and pathology of the aerodigestive tract ERBBs in the gastrointestinal tract: recent progress and new perspectives.Emerging drugs for esophageal cancer.Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy.Targeted therapies for metastatic esophagogastric cancer Emerging tyrosine kinase inhibitors for esophageal cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Emerging mAbs for the treatment of esophagogastric cancer.Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.

P2860

Q26776198-B4DB3463-3B77-4E8D-B32C-CC0F5A0FC26A Q27011232-67EE9967-94AC-4F5C-8049-0FAC6EF4BF2D Q27853223-528FA409-8E8F-43FB-A096-401330AE2820 Q28551507-64CB804B-E799-49E2-9269-393204824E4F Q30245279-F3C3A846-BEE3-45FE-9F27-C8ECEAFFD6FA Q33327744-BDF80955-7624-40B4-8AEA-B50968F2DBED Q33592904-7E56DAE3-5969-40EE-8D68-6BB969817746 Q33947954-D7D5D822-457F-4AF8-AD27-4D4432D2B847 Q34753345-1BF8EA83-19FC-47F0-BF4F-43AC733616D3 Q35130286-E6DD8436-B61C-4F3D-B291-E2FFBD13BED4 Q35624456-1B4D8192-EF32-4417-BB49-BA4A260D90FE Q35625349-EB8DC099-508B-49E1-9F17-1C1046B859D2 Q35667892-942FD520-934C-47BB-B586-C1D88E5E374C Q35870351-F58B30C8-7CCC-4D70-868A-86C171983BFE Q36027475-6C7F223F-CED0-465A-A89A-3C59F68351BE Q36076031-7B1D874C-7A82-4A49-B7A6-01CAE3361740 Q36210986-68D9034C-C679-487F-987E-03EB0E7EF1D2 Q36334562-B02FE34B-6DE1-4B06-A271-29401EEF63AB Q36475391-D4420FFC-C1A6-4A79-A97C-ADD7F16A5044 Q36517741-393260C9-259E-4CAF-93F6-E27C11163913 Q36526959-B963D5C3-58A8-41C2-895C-5D74CF774641 Q36636695-A039CC89-E122-45F0-9293-4B8162E89BC4 Q36801223-E932C6C8-1D90-40ED-9814-A270DC39A09B Q36895413-2B9F599F-EF25-499A-9DD1-89089F7782A6 Q36996728-6342CF6C-9CBF-4F30-874A-F2D90368F6E4 Q37121410-33C6B7AE-0937-484C-82AC-C67702E6F80C Q37263452-8FCF5ADC-FE83-42E2-A38D-FD541AF694F0 Q37337542-3139CE27-DEDA-4472-9FC4-28FD08DCCE4B Q37488281-64A01C83-446D-44AB-99F1-B2A31A33DE3A Q37652493-D1BFDAC4-A8BC-40ED-A204-34792A1C4E38 Q37836513-E2CB18E2-DE94-48C5-B2EC-0FF063A7FC5A Q38110962-0E036199-C0C9-4275-A59E-D337556C6369 Q38221886-82890D67-8548-4849-AAE5-00839C296667 Q38284597-2EB97D00-52C0-4437-8C2E-1B25F6EC1421 Q38385570-E554EF02-F4BC-4011-8FB8-70911577CC11 Q38412375-6C97E6BF-6C08-4FBA-BABD-F4C6DF1D870B Q38893852-561A0A52-5D51-493F-9398-1C1FB01D9FE6 Q39015925-5D28A380-83F6-433A-883C-09CF439BF5A1 Q39385922-F00DE37B-93D2-47A3-82A2-CA21757C8C5A Q39400573-F10377D5-0B19-4BC8-A7F2-319E9C0086A1

P2860

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.

http://www.wikidata.org/entity/Q36614881

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@ast

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@en

type

label

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@ast

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@en

prefLabel

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@ast

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@en

P1433

Q36614881-615282C2-FCEB-4B29-8FB7-E990679F3BD3

P1476

Q36614881-63F8EC60-4F5F-464A-B748-7CBB992786B3

P2093

Q36614881-2B29474A-645F-4696-86A8-B1480A365F29

Q36614881-5A4C476E-AB17-4A0C-B9CB-1AEE682B9D3E

Q36614881-807DDE3D-C808-445A-884A-006764E42162

Q36614881-B0E1B705-F888-4ECD-BB2A-9D1462B0FEBB

Q36614881-DC064B50-1968-45DC-9CA1-4DA78F66BD3F

Q36614881-E36DBE86-E628-4C14-8009-5D22019D6F32

Q36614881-F4552BE2-8F49-4842-8B30-2D44FAC12288

Q36614881-FDF2338E-5685-4B02-8656-034F6C5D197D

P2860

Q36614881-0B11E12D-6124-4EA7-AD7B-D07019010868

Q36614881-0BD6EF98-08B1-4117-9FC2-555863A91BAF

Q36614881-158F5BD6-27C5-44CE-B714-E852FF0545CA

Q36614881-1AA1C169-017B-421E-B7C7-6B25DE77CC82

Q36614881-1BA7DEB8-6BB1-4660-85C8-46A74BA7E29B

Q36614881-1EE99D6C-F065-45E4-A19F-9ADCB44C79D5

Q36614881-27605530-9825-479D-BA48-AD86680BE931

Q36614881-34B7F13F-28C3-440E-883B-6529FD42272C

Q36614881-3F76FB26-A075-45ED-9B6A-AFEC6EB3813E

Q36614881-44942E52-FCC4-41D0-AF33-62D0DC9F5B25

P2888

Q36614881-4243D57E-4551-414C-9784-822C06C7495B

P304

Q36614881-E422583C-B219-4564-854B-5BE4EC50B7BB

P31

Q36614881-3E525AA1-7670-488F-9608-F3C4ECB8718F

P356

Q36614881-452CEAD1-EADF-4603-8439-02156651C908

P407

Q36614881-356D2B54-A1FE-40AC-92AA-BF06B3E54639

P433

Q36614881-93A3ADEF-98F7-4B16-B24B-0D62FF0F797D

P478

Q36614881-DAAFF18A-6CF2-45D0-98C3-44DCB28A1CB5

P577

Q36614881-02BF9BC9-2EBB-45E0-928E-C08A17CBA758

P5875

Q36614881-67559DBC-4088-4ADE-A40B-9F275B8F4581

P6179

Q36614881-805BBD8F-05FD-4553-BAA3-A265E49371C9

P698

Q36614881-C8A4FBE4-CF21-4D41-AC20-2D8A561C222D

P932

Q36614881-6CD1BDFA-6091-4E83-9F48-71C0C5A7DF46

P356

P1433

British Journal of Cancer

P1476

Diffuse EGFR staining is assoc ...... ophageal squamous cell cancer.

@en

P2093

A Volant

http://www.w3.org/2001/XMLSchema#string

C Bessaguet

http://www.w3.org/2001/XMLSchema#string

J-P Metges

http://www.w3.org/2001/XMLSchema#string

L Gibault

http://www.w3.org/2001/XMLSchema#string

M Robaszkiewicz

http://www.w3.org/2001/XMLSchema#string

N Lagarde

http://www.w3.org/2001/XMLSchema#string

P Lozac'h

http://www.w3.org/2001/XMLSchema#string

V Conan-Charlet

http://www.w3.org/2001/XMLSchema#string

P2860

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Signal transduction by receptors with tyrosine kinase activity

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

The ErbB signaling network: receptor heterodimerization in development and cancer

Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.

The EGF receptor family as targets for cancer therapy.

P2888

P304

107-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602625

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7757973

http://www.w3.org/2001/XMLSchema#string

P6179

1042610094

http://www.w3.org/2001/XMLSchema#string

P698

15986037

http://www.w3.org/2001/XMLSchema#string

P932

2361490

http://www.w3.org/2001/XMLSchema#string